Latest1 information on COVID-19
©2022 Stanford Medicine
Not Recruiting
Trial ID: NCT00233415
Phase II Study to Evaluate the Efficacy of Conventional Chemoradiotherapy Followed by Stereotactic Radiosurgery for Locally Advanced Pancreatic Cancer
Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Professor, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS)
Professor of Radiation Oncology (Radiation Therapy) and, by courtesy, of Neurosurgery
Colleen Haas Chair in the School of Medicine
Inclusion Criteria:- Pancreatic tumors not to exceed 7.5 cm.
- Histologically confirmed malignancies of the pancreas, (ampulla of Vater or
periampullary duodenum, tumors may be included when the head of pancreas is
secondarily involved and unresectable criteria are met).
- Unresectable by CT criteria or unresectable at exploratory laparotomy or laparoscopy.
CT criteria for unresectability include encasement of the superior mesenteric vein
(SMV), portal vein (PV) or invasion of the celiac artery or superior mesenteric artery
(SMA).
- Patients with metastatic disease may be treated if they are symptomatic from the
primary tumor.
- Eastern Clinical Oncology Group performance status 0, 1 or 2. Exclusion
Criteria:Chemotherapy within 1 month of registration.
device: Stereotactic Radiosurgery (Cyberknife)
Not Recruiting
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Stanford Cancer Clinical Trials Office
6504987061